← All organizations
Highest phase reached
Phase 4
First clinical trial
Jul 1, 2006Last known activity
May 8, 2025
Timeline
1980s
- Jan 1, 1986
National Natural Science Foundation of China— Founded
Drugs by trial phase (55 distinct, 45 trials)
Phase 4 (21 own, 0 via acquisition)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (11 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenocarcinoma of Lung
- Angina Pectoris
- Angina, Unstable
- Atherosclerosis
- Brain Neoplasms
- Cardiomyopathies
- Cardiomyopathy, Dilated
- Central Nervous System Neoplasms
- Coronary Artery Disease
- Coronary Disease
- Essential Hypertension
- Gastrointestinal Neoplasms
- Heart Diseases
- Hyperhomocysteinemia
- Hypertension
- Infarction
- Infarction, Anterior Cerebral Artery
- Insulin Resistance
- Lupus Erythematosus, Cutaneous
- Lupus Erythematosus, Systemic
- Lymphoma
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Myocardial Ischemia
- Neoplasm Metastasis
- Neoplasms, Second Primary
- Nervous System Neoplasms
- Neuralgia
- Osteogenesis Imperfecta
- Plaque, Atherosclerotic
- Schizophrenia
- Short Bowel Syndrome
- Syndrome
- Thalassemia
Recent trials (45)
- NCT06937476CollaboratorN/AMay 8, 2025
- NCT06604611CollaboratorPhase 4Oct 31, 2024
- NCT06462417CollaboratorN/AJun 20, 2024
- NCT05700266CollaboratorPhase 2/Phase 3Dec 30, 2023
- NCT05814770CollaboratorPhase 4May 31, 2023
- NCT06270394CollaboratorN/AApr 28, 2022
- NCT06355843CollaboratorN/AApr 28, 2022
- NCT04850950CollaboratorPhase 4Apr 26, 2021
- NCT04946669CollaboratorEarly Phase 1Feb 1, 2021
- NCT04403347CollaboratorPhase 1/Phase 2Jun 30, 2020
- NCT04406129CollaboratorPhase 1/Phase 2Jun 1, 2020
- NCT04661709CollaboratorPhase 4Jun 10, 2019
- NCT03877471CollaboratorPhase 1Apr 3, 2019
- NCT03779646CollaboratorPhase 2/Phase 3Jan 16, 2019
- NCT03392298CollaboratorPhase 4Dec 1, 2017
Details
- Founded
- Beijing, CN Jan 1, 1986
- Last known activity
- May 8, 2025